Sugi Predict

Sugi Predict / Compounds / SCHEMBL1991706

SCHEMBL1991706

SCHEMBL1991706

CC(C)(C)OC(=O)N1CCCCC1c1ccc(N)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.47
▸ NR1H2 P55055 4/20 0.45
▸ NPC1 O15118 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ LMNA P02545 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TMEM97 Q5BJF2 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ PPID Q08752 1/20 0.41
▸ NR1H3 Q13133 3/20 0.41
▸ PDE8B O95263 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791760 0.96 RIPK1 (0.51) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL17645281 0.96 RIPK1 (0.51) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL30912588 0.96 RIPK1 (0.51) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL23646472 0.88 RIPK1 (0.48) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL21611486 0.88 RIPK1 (0.48) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL26693383 0.87 GPR119 (0.52) RIPK1NPC1ALDH1A1
SCHEMBL29212195 0.86 RIPK1 (0.47) RIPK1NPC1ALDH1A1
SCHEMBL29330841 0.86 NR1H2 (0.53) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL2130466 0.86 NPC1 (0.48) RIPK1NR1H2NPC1ALDH1A1LMNA
SCHEMBL28448215 0.86 NR1H2 (0.53) RIPK1NR1H2NPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119630651-A Bifunctional compounds containing substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway 霖康疗法公司 2025-03-14 — — CN disclosed
CN-119630644-A Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway 霖康疗法公司 2025-03-14 — — CN disclosed
CN-115557933-B Bruton tyrosine kinase and mutant degradation agent, composition and application thereof 杭州和正医药有限公司 2024-08-16 — — CN disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
CN-115557933-A Bruton tyrosine kinase and mutant degradation agent, composition and application thereof 杭州和正医药有限公司 2023-01-03 — — CN disclosed
EP-3187490-B1 SUBSTITUTED BENZAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2022-04-06 — — EP disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 — — US disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 — — US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 — — US disclosed
EP-2438066-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES Cephalon, Inc. (US) 2012-04-11 — — EP disclosed
WO-2011076678-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-30 — — WO disclosed
WO-2011076678-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-30 — — WO disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 — — WO disclosed
CN-1131222-C Benzamide derivatives and their use as inhibitors of APOB-100 secretion GLAXO GROUP LTD (GB) 2003-12-17 — — CN disclosed
CN-1334808-A Benzamide derivatives and their use as inhibitors of APOB-100 secretion GLAXO GROUP LTD (GB) 2002-02-06 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061760-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R RIPK1 4650/4885NR1H2 284/4885NPC1 937/4885
US-20110152245-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R RIPK1 4650/4885NR1H2 284/4885NPC1 937/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK RIPK1 1331/4885NR1H2 2672/4885NPC1 4341/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R RIPK1 4650/4885NR1H2 284/4885NPC1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.